SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle shares are facing downward pressure and volatility as investors react to a planned $7.5 billion share sale by chairman Larry Ellison alongside concerns regarding the company's high capital expenditure and debt levels. Despite reporting strong quarterly earnings and a significant AI-related backlog, many traders remain frustrated by the stock's inability to sustain post-earnings gains and widespread speculation about institutional manipulation.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

Shares of SLS are sliding as traders speculate on a potential leak or negative developments regarding the Phase 3 REGAL trial, fueled by a circulating third-party survival model and increased put option activity. While the company has released no official clinical updates, the community remains divided between those interpreting the decline as a coordinated short-selling attack intended to shake out retail holders and those concerned about the trial's timeline and success probability.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovin is experiencing significant volatility as investors debate the company's valuation against market-wide software sector trends, with many traders expressing frustration over repeated intraday price reversals. While some community members view the current price action as institutional accumulation and manipulation, others are concerned about potential tax-loss selling and a lack of near-term catalysts before upcoming earnings.

Onyx is an infrastructure for a multi-asset, scalable, and cryptographically secure ledger. Onyx functions as a blockchain-based technology that enhances financial ecosystems by enabling a more efficient and interconnected economy, with a mission to develop cryptographic ledgers that optimize security, scalability, and usability. XCN is native to the Onyx XCN Ledger Blockchain as well as the Onyx Goliath Blockchain. XCN is also used as an ERC-20 token for Staking and Governance.

Onyxcoin

Onyxcoin is experiencing significant volatility as the community debates whether recent price swings represent a genuine technical breakout supported by infrastructure development or a recurring pump-and-dump scheme. While some traders point to potential institutional adoption and neobank-related developments as long-term catalysts, others remain highly skeptical, citing concerns over token dilution and historical price patterns.

Amplify Commodity Trust - Breakwave Tanker Shipping ETF

Breakwave Tanker Shipping ETF

The community is closely monitoring BWET due to its function as a proxy for crude oil tanker shipping rates, with sentiment heavily driven by geopolitical tensions, particularly surrounding shipping disruptions in the Strait of Hormuz and the Red Sea. Traders are actively debating whether these disruptions will continue to support the ETF's upward momentum or if a potential resolution or ceasefire could trigger a sharp correction.

Xanadu Quantum Technologies Ltd. engages in the provision of quantum computing solutions for enterprise and government customers. The company was founded by Christian Weedbrook on October 2, 2025 and is headquartered in Toronto, Canada.

Xanadu Quantum Technologies Ltd. - Ordinary Shares - Class B (Sub Voting)

Xanadu Quantum Technologies is trending following the official release of Backline, an open-source platform co-developed with AMD for rapid quantum-classical communication, alongside a collaboration with ASML to advance photonic chip lithography. Traders are debating the company's long-term potential versus concerns over high cash burn, future dilution, and the highly speculative nature of its hardware roadmap.

Hunter Biden’s Laptop (LAPTOP) is a memecoin referencing the eponymous Hunter Biden laptop sensation that’s been a fixture in global media news cycles for the past six years. LAPTOP is a fungible, freely transferable, non-yield-bearing ERC-20 token on Base. As a memecoin, LAPTOP has no utility, but incorporates two novel distribution mechanics designed to promote long-term community growth: a large community airdrop and an event-based supply mechanism.

Hunter Biden's Laptop

The LAPTOP token is experiencing intense scrutiny and a sharp decline in value following a launch that many traders have labeled a rug pull. The community is largely divided between those criticizing the project as a speculative scam and others mocking participants for investing in a high-risk memecoin.

Lowe's Companies, Inc. engages in the retail sale of home improvement products. The firm offers products for maintenance, repair, remodeling, home decorating, and property maintenance. It also provides home improvement products in the following categories: appliances, seasonal & outdoor living, lumber, lawn & garden, kitchens & bath, hardware, building materials, millwork, paint, rough plumbing, tools, electrical, flooring, and décor. The company was founded in 1946 and is headquartered in Mooresville, NC.

Lowe`s Cos., Inc.

Lowe's Companies, Inc.

Lowe's shares are trending as the stock continues to pull back amid concerns over softening consumer demand for discretionary home-improvement projects and broader housing market headwinds. While some traders view the recent downward price action as an accumulation opportunity near long-term support, others express caution, highlighting mixed recent performance in the sector and persistent DIY spending pressure.

Oklo, Inc. engages in the development of fission reactors. It provides clean energy through the design and deployment of fast fission power plants. The company was founded by Jacob DeWitte and Caroline Cochran on July 3, 2013 and is headquartered in Santa Clara, CA.

Oklo Inc. - Ordinary Shares - Class A

Oklo Inc.

Oklo is facing significant selling pressure primarily driven by concerns over a new $1 billion at-the-market equity offering, which has sparked widespread frustration among investors regarding dilution. While some traders are expressing bearish sentiment due to executive insider selling and skepticism over project timelines, others are viewing the price decline as a buying opportunity, citing long-term prospects in the AI data center energy sector.

AstraZeneca Plc is a global, science-led biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines. Its portfolio spans oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal & metabolism, and respiratory & immunology. The company was founded in 1913 and is headquartered in Cambridge, the United Kingdom.

Astrazeneca plc

AstraZeneca PLC

AstraZeneca's stock is trending following the failure of a late-stage breast cancer trial for Etcamah, which missed its primary endpoint and undercut the case for its broader use in newly diagnosed patients. Traders are expressing concern over the missed trial and a series of recent pipeline setbacks, which has sustained bearish sentiment despite the company's core oncology sales.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Innate Pharma to Host Conference Call and Webcast on September 17 for First Half 2026 Financial Results and Business Update

Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company), today announced that the Company will hold a conference call on Thursday, September 17, 2026 at 2:00 p.m. CEST / 8:00 a.m. EDT, to provide a business update for the first half of 2026. Participants in the...

Innate Pharma to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company), a clinical-stage biotechnology company developing immunotherapies for cancer patients, today announced that members of its executive team will participate in a fireside chat and one-on-one investor...

Innate Pharma Announces Conference Call and Webcast

Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company), today announces that the Company will hold a conference call on Friday, August 14, 2026 at 2:00 p.m. CEST / 8:00 a.m. EDT. Participants during the call will be: Jonathan Dickinson, Chief Executive Officer...

Innate Pharma Jumps as Sobi Deal Boosts Secured Financing for Advancing Rare Skin Cancer Therapy

Sobi and Innate Pharma partner for a Phase 3 trial of lacutamab targeting rare skin cancer, featuring a $75 million upfront payment.read more...

Innate Pharma Lands Major Lacutamab Lifeline as Phase 3 Push Accelerates

Innate Pharma (NASDAQ:IPHA) is entering a potentially pivotal new chapter after announcing plans to advance lacutamab toward the TELLOMAK-3 Phase 3 study following its strategic partnership with Sobi. The deal provides a significant financial catalyst at a critical point in development, with Innate expecting a $75 million upfront payment upon closing and additional near-term development milestones. The company says the proceeds are intended to support TELLOMAK-3 and a planned filing for accelerated approval of lacutamab in Sézary syndrome, while extending its projected cash runway through the third quarter of 2027.

Sobi enters strategic partnership with Innate Pharma to license lacutamab in T-cell lymphoma

Sobi enters strategic partnership with Innate Pharma to license lacutamab in T-cell lymphoma Sobi enters strategic partnership with Innate Pharma to license lacutamab in T-cell lymphoma PR Newswire STOCKHOLM, Aug. 10, 2026 STOCKHOLM, Aug. 10, 2026 /PRNewswire/ -- Swedish OrphanBiovitrum AB (publ...

Innate Pharma to Advance Lacutamab Towards Phase 3 Following Partnership With Sobi and Appoints New Chief Medical Officer

Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company) today announced that, subject to the closing of its strategic partnership with Sobi, it plans to initiate the TELLOMAK-3 confirmatory Phase 3 study of lacutamab in cutaneous T-cell lymphoma (CTCL). Innate...

Innate Pharma Enters Strategic Partnership With Sobi to License Lacutamab in T-cell Lymphoma

Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") and Swedish Orphan Biovitrum AB (publ) (Sobi) today announced that they have entered a strategic partnership to enable initiation of the TELLOMAK-3 confirmatory Phase 3 study in cutaneous T-cell...

Innate Pharma to Participate in a Bladder Cancer Panel at the BTIG Virtual Biotechnology Conference

Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company), a clinical-stage biotechnology company developing immunotherapies for cancer patients, today announced that Sonia Quaratino, EVP Chief Medical Officer of Innate Pharma, will participate in the panel...

Innate Pharma Announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-drug Conjugate (ADC)

Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company"), today announced the completion of enrollment in the dose escalation of the Phase 1 study of IPH4502 (NCT06781983), its proprietary Nectin-4 exatecan ADC. Preliminary data are expected by year-end and...

Innate Pharma SA is a global, clinical-stage biotechnology company, which engages in developing immunotherapies for cancer patients. Its product pipeline includes Lacutamab, Monalizumab, Avdoralimab, and IPH62. The company was founded by Hervé Eloi Dominique Brailly, Eric Vivier, Marc Bonneville, Alessandro Moretta, Jean-Jacques Fournié, and François Romagné on September 23, 1999 and is headquartered in Marseille, France.

Innate Pharma - ADR

IPHA Stock Soars Pre-Market After FDA Clears Late-Stage Trial For Lacutamab In Rare Skin Cancers

Equity

Bearish Sentiment

President Trump has promised to issue a $5,000 "dividend" check to every adult American citizen if the Republican Party wins control of both the House and the Senate in the upcoming midterm elections, though the proposal would require congressional approval and follows his earlier $2,000 tariff-dividend plan, which stalled after the Supreme Court struck down much of his tariff authority. Do you think the $5,000 dividend check actually happens? Vote and explain your reasoning in the comments.

Trump has pledged a $5,000 &quot;dividend&quot; check to every adult American citizen if Republicans win control of both the House and Senate in the midterms. Do you think it actually happens?

Stocktwits

Trump has pledged a $5,000 "dividend" check to every adult American citizen if Republicans win control of both the House and Senate in the midterms. Do you think it actually happens?

Feed

News

Sentiment

Earnings

Fundamentals

Info

IPHA Innate Pharma

Fundamentals

Latest IPHA News